While it is positive to see the CEO purchase shares because it shows his confidence in the company, it also tells me that nothing major is coming down the pipe in the near future. If he purchased shares having insider information...like a possible merge or partnership is about to happen...then it is illegal to do so. More than likely this, publicized, purchase of a large volume of shares was in an effort to reincarnate the buyers so the stock doesnt fall below the NYSE threshold. IMO had he really had confidence in the company he would have purchased when it was $5 or $10...and not when the stock was around an all time low since its uplist.

This should make you hungry...

The head extractor at Medpharm posted a video on LinkedIn of cannabis extract just flowing. His comment was, "We here at Medpharm continue to push boundaries with yields, potency and consistency. Using our unique proprietary techniques and great scientific minds, we are able to produce up to 1 kilo in 150 mins with 90%+ cannabinoids."

Happy Thanksgiving All!

https://www-forbes-com.cdn.ampproject.org/c/s/www.forbes.com/sites/janetwburns/2018/03/18/who-report-finds-no-public-health-risks-abuse-potential-for-cbd/amp/

https://www.nytimes.com/aponline/2019/11/26/business/ap-us-juul-dc-lawsuit.html

It makes sense...however to someone following the company you can read between the lines that it is going well. Initial $1M for the start of research...to a max if $12M achieving certain benchmarks. But the real tell are the two adds to Lexaria's board. The frustrating thing to me is that Altria had no issues adding extra zeros when they made a $1.8B investment in CRON...and the 12.8B investment Juul (which ended up being $4.5B)...whereas the best Lexaria could get was an initial $1M investment. Maybe the pen ran outta ink? All I know is that the deal better be backend heavy...if and when products hit the shelf...either that or Lexaria should have gotten into the vaseline business.

In all honesty, CBD doesnt work for me. I tried 3 different full spectrum versions for 60+ days and it had little effect....but I am not disputing people's claims that it does help them.

Fdc4, the government lists it as a schedule 1 drug -- meaning no medical benefit -- yet found enough "proof" to approve it for Epidiolex. Studies have proven the medical side of cannabis since Sir William O'Shaughnessy in the 1840s. And worst of all, the Department of Health and Human Services holds a patent on certain parts of the plant for "the potential use of non-psychoactive cannabinoids to protect the brain from damage or degeneration caused by certain diseases, such as cirrhosis."
The patent also covers cannabinoids that are useful in treating things like Alzheimer’s, Parkinson’s, and HIV dementia.

My opinion has always been the same. ACB might be a major player years down the road...if they can whither the storm. I know that they keep hinting at a partnership but two things cause me to think that is still a ways off. One, they wanted to establish themselves as a dominate, stand alone, company before the deal...and partnering now would be like buying them for pennies on the dollar (but could also happen if the company is about to go under, as a move to save them). And two, any big partner watching the space sees the current headache that Canopy is to Constellation Brands...and that company might not want to have to deal with the same extremely negative balance sheet.

I honestly think, the stocks with the best short term potential are the ones that operate in the US because even if the US doesn't legalize at the federal level there are other potential catalysts that could cause cannabis stocks to soar. They are the fact that states are constantly evaluating whether or not to recreationally legalize (most are already legal from a medical perspective), the Safe Banking Act, the STATES Act and the possibility of cannabis being removed as a Schedule 1 drug.

I personally don't want to wait 2 to 5 years for things to happen. I prefer that they happen in a year or less and then continue to grow in the next 2 to 5 years. Here's hoping anyone that invested in the industry sees gains in the near future.

Not to rain on your parade but you can cross US Federal Legalization and CBD off that list for the next who knows how long. The FDA just released their decision on CBD. They started their research in 2018! If they can't make up their mind on the non-psychoactive component of cannabis do you really think the short term will also include a decision on the psychoactive component, THC? Here is an article. Tomorrow the industry could see another down day.

FDA updates stance on CBD, pot stocks dip
By Max A. Cherney
Published: Nov 25, 2019 6:39 p.m. ET

The U.S. Food and Drug Administration said late Monday that it cannot conclude that cannabidiol, or CBD, is generally recognized as safe among experts for its use in human or animal food. As a part of the announcement, the FDA said it had warned 15 companies around the U.S. that they were illegally selling products containing CBD, a nonintoxicating cannabinoid found in the cannabis plant. The revised consumer update issued late Monday discusses safety concerns around CBD use and potential liver injury, as well as side effects such as drowsiness, gastrointestinal distress, and changes in mood. The FDA said it plans to continue to issue updates as it learns more about CBD. The revised consumer update included the warning that it is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.

Well the FDA released an unfavorable opinion on CBD:

FDA updates stance on CBD, pot stocks dip
By Max A. Cherney
Published: Nov 25, 2019 6:39 p.m. ET

The U.S. Food and Drug Administration said late Monday that it cannot conclude that cannabidiol, or CBD, is generally recognized as safe among experts for its use in human or animal food. As a part of the announcement, the FDA said it had warned 15 companies around the U.S. that they were illegally selling products containing CBD, a nonintoxicating cannabinoid found in the cannabis plant. The revised consumer update issued late Monday discusses safety concerns around CBD use and potential liver injury, as well as side effects such as drowsiness, gastrointestinal distress, and changes in mood. The FDA said it plans to continue to issue updates as it learns more about CBD. The revised consumer update included the warning that it is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.

This can't be good for NBEV:

FDA updates stance on CBD, pot stocks dip
By Max A. Cherney
Published: Nov 25, 2019 6:39 p.m. ET

The U.S. Food and Drug Administration said late Monday that it cannot conclude that cannabidiol, or CBD, is generally recognized as safe among experts for its use in human or animal food. As a part of the announcement, the FDA said it had warned 15 companies around the U.S. that they were illegally selling products containing CBD, a nonintoxicating cannabinoid found in the cannabis plant. The revised consumer update issued late Monday discusses safety concerns around CBD use and potential liver injury, as well as side effects such as drowsiness, gastrointestinal distress, and changes in mood. The FDA said it plans to continue to issue updates as it learns more about CBD. The revised consumer update included the warning that it is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.

Well the FDA released an unfavorable opinion on CBD...

FDA updates stance on CBD, pot stocks dip
By Max A. Cherney
Published: Nov 25, 2019 6:39 p.m. ET

The U.S. Food and Drug Administration said late Monday that it cannot conclude that cannabidiol, or CBD, is generally recognized as safe among experts for its use in human or animal food. As a part of the announcement, the FDA said it had warned 15 companies around the U.S. that they were illegally selling products containing CBD, a nonintoxicating cannabinoid found in the cannabis plant. The revised consumer update issued late Monday discusses safety concerns around CBD use and potential liver injury, as well as side effects such as drowsiness, gastrointestinal distress, and changes in mood. The FDA said it plans to continue to issue updates as it learns more about CBD. The revised consumer update included the warning that it is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.

With Lexy, I have been getting really good at 'what if' and 'dreaming'. I am sure it is just a matter of time...and more time.

Heck yeah...especially because most medications are taken at the onset of symptoms. For example, when I get a headache I take Ibuprofen. Who wants to wait an hour for it to kick in? Right now we accept the time it takes before we feel relief...but we all wish it would work instantaneously.

The problem is, it's a fake pump...

Do you really think this will pass the senate? It will be squashed, or delayed to the 100th degree, but big Pharma. Look how long it is taking the FDA to make a ruling on the non-psychoactive (CBD) component.

In my opinion we are still years away for federal legalization. At its best I think we will see some happy medium (which wont benefit ACB or the other major Canadian players not allowed to directly operate in the US industry).

Best case for the short term is that cannabis gets downgraded from its current Schedule 1 listing and added to the STATES Act.

Do you really think something will happen? Look how long it is taking the FDA to make a ruling on the non-psychoactive (CBD) component. In my opinion we are still years away. At its best I think we will see some happy medium which wont benefit ACB or the other major Canadian players not allowed to (directly) operate in the US industry. Best case for the short term is that cannabis gets downgraded from its current Schedule 1 listing and added to the STATES Act.

I am with you MEGA. I have voiced this several times on this board. Federal legalization is not what we want. IMO the second this goes federally legal is the second the market big money comes in and everything will consolidate. The US is the second largest consuming nation...second to Asia...the longer this stays illegal the longer MDCL can strategically branch out, establish deep roots and better position themselves. I also believe that is why the deal with Medpharm is so important. I think once federally legal, flower will eventually be a dime a dozen. The real money will end up in specialty plays like derivatives, BUT MAINLY, research/pharmaceuticals. If the nation stays federally illegal MDCL can continue to enjoy the best of all worlds.

https://www.profitconfidential.com/stock/medicine-man-technologies-stock/medicine-man-technologies-inc-cannabis-stock-bucking-downturn/

Analyst Take
Medicine Man Technologies Inc won’t be an under-the-radar cannabis stock much longer. The company has been on an acquisition frenzy since May, which will see it become one of the largest seed-to-sale cannabis operators in North America.

Those acquisitions are all expected to close late in the first or second quarter of 2020. This is something that investors might want to keep in mind, with MDCL stock currently trading around $3.00 per share.

Albert Gutierrez posted on LinkedIn that LeafLink, a cannabis industry wholesale market place, listed the Medpharm 20:1 Aliviar Tincture as 2019 Top 5 best selling tincture in the country. If you go to the Leaflink 2019 winner website they actually have the product in the #1 position under Tinctures & Sublinguals.

It's rebounding. Hopefully FOMO for these prices drives this back up in a heartbeat.

All the Canadian cannabis stocks are taking a huge hit. I bailed on that one back at the $10 range...and moved US. What really sucks is that Lexaria is still attached to Canadian cannabis industry and until they finally release news on Nicotine or Pharm they will probably continue to follow the same ebbs and flows.

This is an interesting read. MDCL is mentioned because they are acquiring farms in Pueblo County and could be impacted if the law changes:

https://www.chieftain.com/news/20191116/pueblo-county-farmer-asks-to-extend-pot-cultivation-buffer

Also nice to hear (nothing specific...but implied) that there are other products/agreements in the works that will utilize Lexy's tech.

Recent Proactive Hill Street Beverage Interview:

Same here. Even though most of the MDCL shareholders understand what they own...here's hoping for a quick spike down right when the market opens from people scared of the industry and just want out of the sector entirely.

According to Andy you both are correct. Debit cards are accepted...you no longer need to pay in cash...but credit cards are still not allowed.

I am with you stockman...

Actually I kinda appreciate the current downtrend because it has given me time focus most of my money into other (really one other) investments.

The other problem is that the are not plant touching. I mean, ok, you can be an IP company that licenses your technology but if you are licensing it to a company who wants to enter the space...say an existing beverage company wanting to add a CBD beverage to their portfolio...that will also require the beverage company to partner with a CBD producer capable of integrating Lexaria's technology into their process. What company wants to jump through multiple hoops when there are other technologies out there...that might not have the extensive research to back up their claims or might not be truly water-soluble, but they are enough to the naked eye...that is capable of accomplishing both steps?

That is also why their 10-year agreement with Hill Street is so important because this will consolidate the steps. The other problem is...that isn't quite up and running yet either.

Well Cramer, on CNBC Street Signs (today), just slammed the entire industry and basically apologized to his cult-following. He stated that the sector hasn't been as expected and advised to stay away...stating that all these companies need to just burn their excess supply.

Personally, I read and watch "analyst" commentary on the industry...but the sector is so new, and constantly evolving, that I don't take anything I retain as gospel. What they are spewing is to support their current position in the sector...whether it be short or long.

My perception: The major players in this industry are like a group of women...now that they have been lumped together the cycling has started...and will continue. It only takes one to trigger the emotional roller coaster that we see every day.

Experts: $140M cannabis acquisition signals turning point for Colorado industry

By Monica Vendituoli – Reporter, Denver Business Journal
Nov 13, 2019, 1:10pm MST
New York-headquartered cannabis company Columbia Care revealed last week that it plans to acquire The Green Solution, Colorado’s largest cannabis company, in a $140 million deal.
Colorado industry experts told Denver Business Journal they see the deal as a long-awaited turning point for exponential growth of the state’s newest sector.
“The acquisition of The Green Solution by [Canadian-traded] Columbia Care reaffirms what we already knew — the global cannabis industry has their eyes on Colorado,” said Andy Williams, CEO and co-founder of Medicine Man Technologies. “... Much like how other states were looking to Colorado as a guide for establishing medical and recreational programs, businesses and entrepreneurs will be exported from Colorado to lead the national cannabis economy.”
Williams’ Denver-based cannabis company itself is on a buying spree and has announced several big-name acquisitions of its own in recent months. All these acquisitions were made possible by Gov. Jared Polis’ signing of House Bill 1090 this past June. The new law allows publicly traded companies to have cannabis licenses for the first time in Colorado. Additionally, the law permits more investments in the state’s cannabis industry by venture capitalists and other private equity firms by removing the previous limit of 15 out-of-state owners per cannabis company in the state.
Columbia Care is traded on the Toronto, Canada-based NEO Exchange, an alternative stock market. Despite that listing, Columbia Care does not employ any people in Canada and is headquartered in New York City, according to the company.

If I had to guess it is because there is a definitive 120day deadline before something happens...unless something happens with Medpharm before then. I assume most would see this as an opportunity to go somewhere else and come back closer to the deadline...and probably get back in around the same share price.

It doesn't appear to be anytime soon...at least not until early 2020. Hill Street's new bottling partner hasn't even received it's Health Canada license to produce cannabis beverages. The best thing that could happen is Altria news, which is not likely because the funding from Altria was on multi-year research project...or we find out that someone else has decided to license their tech for edibles or beverages, but that would have through the Lexy/Hill Street deal/license since Lexy doesn't touch the plant.

Posted by someone on the Yahoo board:
https://www.simplifya.com/simplifya-news/medicine-man-technologies-andy-williams-controls-the-universe/

Drugdoctor, your right. Still legal issues with in New Zealand with cannabis...but none the less still exciting news!

“We’ve been impressed with the science-based research, processes, formulation and testing MedPharm has completed on various applications for medicinal cannabis products,” says Nature’s Answer Managing Director Angela Calver.

Medicine Man Technologies itself has expressed a keen interest in New Zealand, “Our market is attractive predominantly because it doesn’t have the multiple layers of government and bureaucracy which can limit the pace at which new pharmaceutical products can be brought to market,” Calver notes.

“The minute the law allows it, we’ll import while at the same time gearing up our own facilities for local manufacturing, leveraging the companies’ proven business model.”

It would have been nice if this was mentioned on the call:

https://markets.businessinsider.com/news/stocks/medicine-man-partners-nature-s-answer-for-cannabis-products-in-new-zealand-1028675836

I liked the thought of a farm in Columbia (ideal climate and cheap labor) with the ability to import/export globally...and their own research facility. Didn't Green Equity SAS seek out Medicine Man Technologies and essentially make them an offer 'that they couldn't refuse'? The deal was small compared to some of the other announced pending-acquisitions. I am not questioning why they decided to back out. I am sure they did it because it was in the best interest for Medicine Man and the companies vision. I just wonder what made them decided to terminate the contract.

Absolutely could. No debating that one. Chances are Lexaria technology isn't even on their radar. More than likely they will just wait for a CBD beverage company to come out, be a hit (hit 10M in sales) and then consider acquiring them. Obviously I am bias when it comes to Lexaria, but the more you think about it the more it makes sense for Lexaria (through the Hill Street license) to supply them with CBD powder and they can decide what product, or products, to add it to. I would think Powerade would be one of their first products in order to compete directly with Canopy/Constellations BioSteel. Another obvious option would be to add it to a sparkling water...since they are apparently all the rage right now.

Did I hear this correctly? When the term sheet reached its deadline, MDCL decided to no longer pursue Green Equity SAS and instead decided to continue to focus on the state of Colorado?

I saw this posted over the weekend; two articles, this one and another article from 11/3. Seeing how challenging the partnership with Canopy and Constellation Brands has been I would think that any large, established, company would not want to follow in Constellations footsteps....especially, if Coca-Cola only wants to try the CBD space. There are technologies out there that could accomplish their mission without the frustration...and at a fraction of the cost. Lexaria (with the help of the Hill Street license) would be the obvious choice because Lexaria's has several years of CBD research to support its technology...and especially the newer research to support the technologies shelf life stability.

https://www.westword.com/marijuana/denver-marijuana-business-owners-welcome-the-challenge-of-public-companies-and-big-money-11543285